Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Target Recruit Count
- 27
- Registration Number
- NCT00006373
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 378
- Registration Number
- NCT00027846
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 213
- Registration Number
- NCT00005985
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT00032019
- Locations
- 🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸Memorial Regional Hospital Comprehensive Cancer Center, Hollywood, Florida, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 4
- Registration Number
- NCT00006747
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
- First Posted Date
- 2003-01-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00051311
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
- Conditions
- Interventions
- Drug: F-18 FluorodeoxyglucoseBiological: therapeutic allogeneic lymphocytesProcedure: Peripheral Blood Stem Cell donationDrug: cyclophosphamideDrug: cyclosporineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: fludarabine phosphateDrug: melphalanDrug: prednisoneDrug: sirolimusDrug: tacrolimusDrug: vincristine sulfateProcedure: peripheral blood stem cell transplantationDrug: Filgrastim
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00043979
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Lederle Laboratories
- Registration Number
- NCT00002003
- Locations
- 🇺🇸
UMDNJ - New Jersy Med School, Newark, New Jersey, United States
🇺🇸New York Univ Med Ctr, New York, New York, United States
🇺🇸Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States
Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 41
- Registration Number
- NCT00000807
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 24
- Registration Number
- NCT00000660
- Locations
- 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
🇺🇸Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.